Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
In development
Reference number: GID-TA11008
Expected publication date: TBC
Dear stakeholders,
As you will be aware the Department for Health & Social Care has asked NICE to carry out an appraisal of Lenvatinib with pembrolizumab and transarterial chemoembolisation for incurable, non-metastatic hepatocellular carcinoma.
For information, the company have announced that they will no longer be pursuing a Marketing Authorisation Application in this indication at this time.
Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.